Cartesian Therapeutics, Inc.
RNAC
Rangering i aksjer
#18255
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Aksjekurs
$6.32
Markedsverdi
$191.22M
Endring (1 dag)
3.95%
Endring (1 år)
847.12%
Land
US
Handel Cartesian Therapeutics, Inc. (RNAC)
Kategori
Healthcare
Historikk for aksjesplitt for Cartesian Therapeutics, Inc. (RNAC)
Aksjen Cartesian Therapeutics, Inc. (symbol: RNAC) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Oct 20, 2026.
Én RNAC-aksje kjøpt før Oct 20, 2026 tilsvarer i dag 0 RNAC-aksjer.
Den nyeste splittelsen skjedde Oct 20, 2026.
Én RNAC-aksje kjøpt før Oct 20, 2026 tilsvarer i dag 0 RNAC-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| Ikke nok data for de angitte datoene. | |||
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
